Utility values for specific hepatic encephalopathy health states elicited from the general public in the United Kingdom

Health and Quality of Life Outcomes

Rob Barden²  Kam Nanuwa²  Julian F Guest¹ 

[1] School of Biomedical Sciences, King’s College, London, UK;Norgine Pharmaceuticals Ltd, Harefield, UK

关键词: UK;    Utility;    Time trade-off;    Standard gamble;    Hepatic encephalopathy;    Conn grade;   

Others  :  814653
DOI  :  10.1186/1477-7525-12-89

 received in 2013-12-23, accepted in 2014-05-21,  发布年份 2014

【 摘 要 】

Background and aims

To elicit utility values for five health states corresponding to increasing severity of hepatic encephalopathy, from members of the general public in the UK. The health states studied were Conn grades 0, 1, 2, 3 and 4.

Methods

Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities were elicited for the five health states from a random sample of 200 members of the general public in the UK, using health state descriptions validated by clinicians and members of the general public.

Results

Respondents’ mean age was 49.5 years and 49% were female. Mean utilities were 0.962 (TTO) and 0.915 (SG) for Conn grade 0; 0.912 (TTO) and 0.837 (SG) for Conn grade 1; 0.828 (TTO) and 0.683 (SG) for Conn grade 2; 0.691 (TTO) and 0.489 (SG) for Conn grade 3; and 0.429 (TTO) and 0.215 (SG) for Conn grade 4. The TTO and SG values between the five Conn grades were significantly different (p < 0.001). Additionally, the TTO value was significantly higher than the SG value for the corresponding state (p <0.0001).

Conclusion

These findings quantify how different Conn grades and level of response to treatment may impact on the health-related quality of life of patients with hepatic encephalopathy. There were greater preference values for lower levels of disease, with the highest value associated with Conn grade 0. These health state preference values can be used to estimate the outcomes of different interventions for hepatic encephalopathy in terms of quality-adjusted life years.

【 授权许可】

   
2014 Guest et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Mullen K, Prakash R: Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010, 4(6):665-677.
• [2]Mahl T, O’Grady J: Fast facts: Liver Disorders. Oxford: Health Press Limited; 2006.
• [3]Mullen KD: Review of the final report of the 1998 working party on definition, nomenclature and diagnosis of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(Suppl 1):11-16.
• [4]Morgan M: Chapter 8: Hepatic Encephalopathy in Patients with Cirrhosis. In Sherlock’s Diseases of the Liver and Biliary System. 12th edition. Edited by Dooley JS, Lok A, Burroughs A, Heathcote J. Blackwell Publishing Ltd; 2011.
• [5]Gilberstadt SJ, Gilberstadt H, Zieve L, Buegel B, Collier RO Jr, McClain CJ: Psychomotor performance defects in cirrhotic patients without overt encephalopathy. Arch Intern Med 1980, 140(4):519-521.
• [6]Gitlin N, Lewis DC, Hinkley L: The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis. J Hepatol 1986, 3(1):75-82.
• [7]Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR: Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001, 16(5):531-535.
• [8]Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY, International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN): Review article: the design of clinical trials in hepatic encephalopathy - an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011, 33(7):739-747.
• [9]Younossi ZM, Boparai N: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001, 96(2):579-583.
• [10]Arguedas MR, DeLawrence TG, McGuire BM: Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003, 48(8):1622-1626.
• [11]Bao ZJ, Qiu DK, Ma X, Fan ZP, Zhang GS, Huang YQ, Yu XF, Zeng MD: Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy. World J Gastroenterol 2007, 13(21):3003-3008.
• [12]Tan HH, Lee GH, Thia KT, Ng HS, Chow WC, Lui HF: Minimal hepatic encephalopathy runs a fluctuating course: results from a three-year prospective cohort follow-up study. Singapore Med J 2009, 50(3):255-260.
• [13]Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, Schalm SW: Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28(1):45-49.
• [14]Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, Bortey E, Forbes WP: Randomised clinical trial: Rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011, 34(8):853-861.
• [15]Kielhorn A, von der Schulenburg JM G: The health economics handbook. 2nd edition. Chester: Adis International; 2000.
• [16]Morris S, Devlin N, Parkin D: Economic Analysis in Health Care. London; Hoboken, NJ: Wiley & Sons; 2007.
• [17]Huang E, Esrailian E, Spiegel BM: The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Aliment Pharmacol Ther 2007, 26(8):1147-1161.
• [18]Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M: Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003, 98(3):630-638.
• [19]Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL: Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997, 127(10):855-865.
• [20]Wong JB, Bennett WG, Koff RS, Pauker SG: Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998, 280(24):2088-2093.
• [21]Shawcross DL, Sharifi Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, Auzinger G, Bernal W, Wendon JA: Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol 2011, 54(4):640-649.
• [22]Hepatic Encephalopathy Available on line at: http://www.patient.co.uk/doctor/Hepatic-Encephalopathy.htm webcite. Last accessed 30 May 2013
• [23]Hammerschmidt T, Zeitler H-P, Gulich M, Leidl R: A comparison of different strategies to collect standard gamble utilities. Med Decis Making 2004, 24:493-503.
• [24]Ara R, Brazier JE: Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health 2011, 14(4):539-545.
• [25]Morimoto T, Fukui T: Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol 2002, 12(2):160-178.
• [26]Stalmeier PF, Lamers LM, Busschbach JJ, Krabbe PF: On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences. Med Care 2007, 45:835-841.
• [27]Guest JF, Sladkevicius E, Gough N, Linch M, Grimer R: Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma 2013, 2013:863056. doi:10.1155/2013/863056. Epub 2013 Mar 17
• [28]Guest JF, Gray EJ, Szczudlo T, Magestro M: Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma 2014. Epub ahead of print
• [29]Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J: Health status versus utilities of patients with end-stage liver disease. Qual Life Res 2004, 13(4):773-782.
• [30]Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM: Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl 2008, 14(3):321-326.
• [31]Adibi P, Akbari L, Kahangi LS, Abdi F: Health-state utilities in liver cirrhosis: a cross-sectional study. Int J Prev Med 2012, 3(Suppl 1):S94-S101.
• [32]McLernon DJ, Dillon J, Donnan PT: Health-state utilities in liver disease: a systematic review. Med Decis Making 2008, 28(4):582-592.